CDKN2A/B半合子缺失在脑膜瘤中的预后影响
基于970例脑膜瘤的多中心队列,利用DNA甲基化数据评估CDKN2A/B半合子缺失的预后意义。总体上半合子缺失与进展风险增加无统计学显著性(log-rank P=.074;HR=1.36,95%CI 0.97-1.90;P=.07),但节段性半合子缺失与显著更差预后相关(log-rank P=.0023),而局灶性半合子缺失无此关联(log-rank P=.523)。
要点
- CDKN2A/B半合子缺失总体不显著增加脑膜瘤进展风险
- 节段性半合子缺失与显著更差预后相关,局灶性则不然
- 节段性缺失可能反映基因组不稳定而非位点特异性效应
核心结论
- CDKN2A/B半合子缺失总体不赋予脑膜瘤更差的进展风险。
- 节段性半合子缺失的信号可能并非位点特异性,而是侵袭性脑膜瘤基因组不稳定的表现之一。
研究设计与样本
- 多中心队列研究,纳入970例脑膜瘤。
- 基于DNA甲基化芯片数据评估拷贝数与突变数据,手工分类CDKN2A/B状态。
- 采用Kaplan-Meier法计算进展概率。
主要发现
- 970例中30例为纯合缺失,114例为半合子缺失(31例节段性,83例局灶性),826例为CDKN2A/B平衡状态。
- 半合子缺失总体与进展风险增加相关但未达统计学显著性(log-rank P=.074;HR=1.36,95%CI 0.97-1.90;P=.07)。
- 节段性半合子缺失与显著更差预后相关(log-rank P=.0023),局灶性半合子缺失无显著关联(log-rank P=.523)。
- 节段性半合子CDKN2A/B缺失比局灶性缺失更常伴随更多高风险拷贝数变异。
临床怎么用
- 评估脑膜瘤CDKN2A/B状态时应区分半合子缺失的节段性与局灶性。
- 节段性半合子缺失可提示基因组不稳定及更差预后,需加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas are the most common adult brain tumors. While homozygous deletions of CDKN2A/B are linked to early recurrence and hence serve as CNS WHO grade 3 criterion, the clinical impact of hemizygous deletions remains unclear-especially since distinguishing between hemi- and homozygous losses can be technically challenging. METHODS: DNA methylation data, copy-number, and mutation data were evaluated on a multicenter cohort of 970 meningiomas. Each sample's CDKN2A/B status was manually classified by visual inspection in relation to whole chromosomal losses and gains in the copy number profile generated from global methylation array data in relation to other copy number events. Progression probabilities were determined using the Kaplan-Meier method. RESULTS: Among 970 meningiomas, n = 30 had homozygous, n = 114 hemizygous (n = 31 segmental; n = 83 focal), and n = 826 CDKN2A/B balanced status. In cases with hemizygous deletions in general, an association with increased progression risk compared to balanced cases was observed, although this did not reach statistical significance (log-rank P = .074; HR = 1.36, 95% CI [0.97, 1.90]; P = .07). However, segmental hemizygous losses were linked to a significantly worse prognosis (log-rank P = .0023), but focal hemizygous deletions were not (log-rank P = .523). Segmental hemizygous CDKN2A/B deletions were more frequently associated with a higher amount of high-risk copy number variations than focal losses. CONCLUSION: Our findings suggest that hemizygous CDKN2A/B deletions overall do not confer worse risks for progression in meningiomas. The signal for segmental deletions may not be locus-specific but just one representation of the generally instable genome of aggressive meningiomas.
引用
- Ippen FM, Hielscher T, Patel A, et al. The prognostic impact of CDKN2A/B hemizygous deletions in meningioma. Neuro Oncol. 2026. PMID: 41671098. doi:10.1093/neuonc/noag024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。